Stanley Holstein
Neurology · New Rochelle, NYNPI 1720148869
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,196 and has fallen 98.0% since, to $45 in 2023.
Across 98 payments — averaging $33.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$637
- Teva Pharmaceuticals USA, Inc.$338
- Novartis$292
- EMD Serono, Inc.$282
- Acorda Therapeutics, Inc$231
- Lilly USA, LLC$179
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$672%
- Food & beverage$3,26198%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $637 |
| Teva Pharmaceuticals USA, Inc. | 3 | $338 |
| Novartis | 14 | $292 |
| EMD Serono, Inc. | 6 | $282 |
| Acorda Therapeutics, Inc | 8 | $231 |
| Lilly USA, LLC | 3 | $179 |
| Sunovion Pharmaceuticals Inc. | 8 | $155 |
| Genentech USA, Inc. | 2 | $154 |
| Biogen | 3 | $131 |
| Adamas Pharmaceuticals, Inc. | 6 | $129 |
| Akcea Therapeutics, Inc. | 1 | $117 |
| Johnson & Johnson | 4 | $93 |
| Lundbeck LLC | 2 | $88 |
| AbbVie | 5 | $86 |
| Avion Pharmaceuticals | 3 | $68 |
| Kyowa Kirin, Inc. | 2 | $57 |
| Amgen | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| PTC Therapeutics, Inc. | 2 | $40 |
| Pfizer | 2 | $40 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| NS Pharma, Inc. | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,328 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 12 | $308 |
| Gabapentin | 30 | $237 |
| Baclofen | 14 | $183 |
| Cyclobenzaprine Hcl | 42 | $153 |
| Donepezil Hcl | 21 | $142 |
| Meclizine Hcl | 14 | $112 |
| Topiramate | 28 | $108 |
| Memantine Hcl | 12 | $102 |
| Ibuprofen | 27 | $64 |
| Zolpidem Tartrate | 15 | $50 |
| Quetiapine Fumarate | 11 | $40 |
| Meloxicam | 18 | $28 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Rochelle
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.